UNICA IRIS Institutional Research Information System

FARCI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 62.350
NA - Nord America 4.450
AS - Asia 584
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
SA - Sud America 1
Totale 67.398
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 61.225
US - Stati Uniti d'America 4.439
UA - Ucraina 450
CN - Cina 424
SE - Svezia 288
FI - Finlandia 107
GB - Regno Unito 106
DE - Germania 105
SG - Singapore 104
FR - Francia 29
IN - India 16
IR - Iran 13
CA - Canada 11
RU - Federazione Russa 11
KR - Corea 9
VN - Vietnam 8
NL - Olanda 7
EU - Europa 4
EG - Egitto 3
HK - Hong Kong 3
IE - Irlanda 3
PK - Pakistan 3
RO - Romania 3
AT - Austria 2
AU - Australia 2
CH - Svizzera 2
DK - Danimarca 2
ES - Italia 2
GR - Grecia 2
IQ - Iraq 2
MU - Mauritius 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
BE - Belgio 1
BR - Brasile 1
CZ - Repubblica Ceca 1
GE - Georgia 1
JP - Giappone 1
LU - Lussemburgo 1
LV - Lettonia 1
Totale 67.398
Salva come PNG Salva come JPEG
Città #
Cagliari 60.286
Uta 748
Fairfield 586
Chandler 481
Woodbridge 450
Houston 362
Ashburn 270
Boardman 256
Ann Arbor 249
Jacksonville 243
Seattle 234
Wilmington 229
Cambridge 200
Nyköping 180
Dearborn 123
Santa Clara 77
Beijing 75
Nanjing 70
Boston 65
Shanghai 48
Singapore 42
Helsinki 36
Milan 32
San Diego 32
Guangzhou 28
Shenyang 26
Hebei 22
Nanchang 22
Verona 20
Changsha 19
Redwood City 18
Jiaxing 17
Sassari 17
Los Angeles 14
Pune 14
Falls Church 13
Norwalk 12
Tianjin 11
Hefei 10
London 10
Mountain View 10
Orange 10
Auburn Hills 9
Guasila 9
Ningbo 9
Renton 9
Seoul 9
Dong Ket 8
Redmond 7
Zhengzhou 7
Jinan 6
Kunming 6
New York 6
Toronto 6
Washington 6
Chicago 5
Atlanta 4
Walnut 4
Augusta 3
Cairo 3
Catania 3
Chongqing 3
Edinburgh 3
Fuzhou 3
Hangzhou 3
Hong Kong 3
Kilburn 3
Taizhou 3
Tehran 3
Ussana 3
Wuhan 3
Amsterdam 2
Auckland 2
Bhubaneswar 2
Cassano d'Adda 2
Cedar Knolls 2
Chengdu 2
Columbus 2
Copenhagen 2
Detroit 2
Dublin 2
Islington 2
Lausanne 2
Madrid 2
Mashhad 2
Munich 2
Oslo 2
Oxford 2
Phoenix 2
Rockville 2
Saint Petersburg 2
San Mateo 2
Thessaloniki 2
Valenzano 2
Vienna 2
Aachen 1
Bethesda 1
Borris 1
Borås 1
Brasília 1
Totale 65.869
Salva come PNG Salva come JPEG
Nome #
Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively 2.915
Liver Regeneration Signature in Hepatitis B Virus (HBV)-Associated Acute Liver Failure Identified by Gene Expression Profiling 2.853
Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively 2.662
Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis 2.578
Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus - associated hepatocellular carcinoma. 2.483
Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma 2.437
Association of chronic hepatitis C with recurrent brief depression 2.346
Integrated ordination of miRNA and mRNA expression profiles 2.261
Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue 2.111
Natural history of hepatitis C in thalassemia major: a long-term prospective study 2.044
null 1.610
Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure 1.596
Epidemiology of infection with HIV-1 in Sardinia: a multicentre prospective study 1.590
Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma 1.572
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 1.561
null 1.445
Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma 1.404
Molecular signature and mechanisms of hepatitis D virus–associated hepatocellular carcinoma 1.404
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype 1.370
Clinical Features of Hepatitis D 1.351
Specificity of an anti-capsid antibody associated with Hepatitis B Virus-related acute liver failure 1.318
New Insights into the HCV Quasispecies and Compartmentalization 1.289
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. 1.210
Experimental transmission of hepatitis C virus associated fulminant hepatitis to a chimpanzee 1.199
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. 1.110
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. 1.056
The use of molecular assays in the management of viral hepatitis 829
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. 777
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy 690
Viral escape and the failure of cellular immune responses 586
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? 577
Treatment of chronic hepatitis D 573
Treatment of patients with Chronic Hepatitis Delta 533
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C 531
Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B 504
Treatment of chronic hepatitis D: New advances, old challenges 502
Chronic viral hepatitis D 499
Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin 482
In Vivo study of the HC-TN Strain of Hepatitis C Virus Recovered from a Case of Fulminant Hepatitis: RNA Transcripts of a Molecular Clone (pHC-TN) are Infectious in Chimpanzees but not in Huh7.5 cells 461
The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase 456
Natural history and experimental models of hepatitis C 449
Hepatitis D (Delta) Virus 437
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome 437
Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection 429
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B 426
Immune Response to Hepatitis C Virus 423
Implicazioni biologiche e cliniche della quasispecie virale 411
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies 408
L’epatite delta 399
null 399
The quasispecies of hepatitis C virus and host immune response 395
Clinical relevance of hepatitis C virus genetic variability 392
A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures 384
Lack of protective immunity against reinfection with hepatitis C virus 372
Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. 367
Hepatitis C virus associated fulminant hepatic failure 365
Long term study of hepatitis C virus replication in non-A non-B hepatitis 353
Evaluation of antibodies to hepatitis C virus in a long-term prospective study of post-transfusion hepatitis among thalassemic children: comparison between first- and second- generation assay 325
Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassemic children 319
Acute viral hepatitis in Saudi Arabia: seroepidemiological analysis, risk factors, clinical manifestations, and evidence for a sixth hepatitis agent. 319
Delta hepatitis: an update 316
Virological mechanisms of viral persistence, resolution and reinfection 313
Milestones in Liver Disease 312
The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. 312
Peginterferon alfa-2a (40 KD) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels 310
Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. 307
Prevention of hepatitis C virus infection in chimpanzee by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein 305
Markers of hepatitis C virus infection in Sardinian blood donors: relationship with alanine aminotransferase levels. 304
Hepatitis C virus. The importance of viral heterogeneity 299
La ricerca biomedica 276
Immunity elicited by hepatitis C virus. 274
Prevention of hepatitis C virus infection in chimpanzee after antibody-mediated in vitro neutralization 272
HCV diversity, dynamics and turnover 265
HCV-associated lymphomas 264
Molecular basis of viral resistance to interferon in chronic hepatitis C 258
Clinical significance of hepatitis C virus genotypes and quasispecies 242
Treatment of chronic hepatitis D with interferon alfa-2a 147
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis 128
Totale 67.488
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.655
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.655
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012.028 0 0 0 0 5.339 3.482 1.680 468 249 203 253 354
2020/202116.044 492 440 492 5.368 3.958 1.346 1.195 889 249 744 514 357
2021/20224.003 303 418 235 246 362 341 282 230 261 293 501 531
2022/20235.574 620 696 748 416 541 495 145 860 333 227 240 253
2023/20244.801 397 263 272 453 462 667 534 317 221 398 445 372
2024/20252.634 499 504 778 525 328 0 0 0 0 0 0 0
Totale 67.488